Table II.

Patient disposition.

	BEZ235 300 mg bid n=20	BEZ235 400 mg bid n=11	All N=31
Treatment, n (%)
Treatment ongoing*	1 (5.0)	1 (9.1)	2 (6.5)
Treatment discontinued	19 (95.0)	10 (90.9)	29 (93.5)
Primary reason for treatment discontinuation, n (%)
Progressive disease	11 (55.0)	4 (36.4)	15 (48.4)
Adverse event	6 (30.0)	5 (45.5)	11 (35.5)
Physician decision	1 (5.0)	0	1 (3.2)
Patient/guardian decision	0	1 (9.1)	1 (3.2)
Death	1 (5.0)	0	1 (3.2)

^*Ongoing at time of data cut-off, 30 June, 2014. bid, Twice daily.